Compare CVS Health Corp (CVS) vs iShares JPMorgan USD Emerging Markets Bond ETF (EMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs iShares JPMorgan USD Emerging Markets Bond ETF — how do they compare? CVS Health Corp trades at $104.03 (market cap $135.48B), while iShares JPMorgan USD Emerging Markets Bond ETF trades at $95.75. The key difference: CVS Health Corp pays a 2.51% dividend while iShares JPMorgan USD Emerging Markets Bond ETF pays none, and CVS Health Corp is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals.
| CVS | EMB | |
|---|---|---|
Market Cap | $135.48B | — |
Sector | Health | Fixed Income |
52-Week High | $106.18 | $97.74 |
52-Week Low | $58.75 | $91.52 |
Enterprise Value | $202.02B | — |
Dividend Yield | 2.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
EMB trades at $95.38, down 0.64% on the day, with a bearish technical signal from moving averages and oscillators. The stock shows oversold conditions with a 6-day RSI at 29.09, while recent corporate actions include scheduled dividends for mid-2026. News coverage highlights emerging market bond risks and Federal Reserve policy impacts on similar ETFs.
The outlook remains cautious due to technical weakness and macro risks in emerging markets. Investment opportunity lies in potential oversold rebound, but risks include sovereign default exposure and interest rate sensitivity. Investor sentiment is mixed amid global fixed income volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →
